Breast Cancer Therapy-Related Cardiac Dysfunction Likely Diagnosed More Accurately With Combined Testing Breast Cancer Therapy-Related Cardiac Dysfunction Likely Diagnosed More Accurately With Combined Testing
In women with HER2-positive breast cancer, combined sequential use of echocardiographic 3-D LVEF with 2-D GLS and GCS provided a more timely and accurate diagnosis of cancer therapy-related cardiac dysfunction than when these measures were used individually.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 22, 2022 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Daily Aspirin Does Not Prevent Recurrence of Breast Cancer
Compared with placebo, daily aspirin did not improve invasive disease - free survival in patients with high - risk, HER2 - negative breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 18, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
Daily Aspirin Does Not Prevent Recurrence of Breast Cancer
FRIDAY, Feb. 18, 2022 -- Regular aspirin use does not improve invasive disease-free survival (iDFS) among high-risk breast cancer patients with human epidermal growth factor receptor 2 (HER2)-negative disease, according to a study presented Feb. 15... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
No Benefit to Adding Trastuzumab for HER2 Esophageal Cancer No Benefit to Adding Trastuzumab for HER2 Esophageal Cancer
In patients with HER2-overexpressing esophageal cancer, adding trastuzumab to neoadjuvant chemoradiation was not effective in a phase 3 trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 28, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
' New Standard of Care' for HER2-Mutant NSCLC?'New Standard of Care' for HER2-Mutant NSCLC?
Patients with non –small cell lung cancer harboring HER2 mutations experienced durable activity and promising survival outcomes with trastuzumab deruxtecan, a new study shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 19, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Triple Therapy for HER2-Positive Gastric Cancer Shrinks Tumors Triple Therapy for HER2-Positive Gastric Cancer Shrinks Tumors
The addition of pembrolizumab (Keytruda) to trastuzumab (Herceptin) and platinum-based chemotherapy led to a significant improvement in overall response rate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer
Patients treated with pyrotinib plus capecitabine survived longer than those treated with lapatinib plus capecitabine in the PHOEBE trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
21-Gene Assay Guides Chemotherapy in Node-Positive Breast Cancer
TUESDAY, Dec. 14, 2021 -- Premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one to three positive lymph nodes and a recurrence score of 25 or lower benefit from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2021 Category: Pharmaceuticals Source Type: news
Ongoing HER2 Therapy May Cost an Additional $68,000 per Patient Ongoing HER2 Therapy May Cost an Additional $68,000 per Patient
Meeting the treatment needs of the nearly 50% of women with metastatic breast cancer in British Columbia who could benefit from continued HER2 suppression would cost at least $68,000 more per patient.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
No Benefit to Adding Palbociclib to Early Breast Cancer Therapy No Benefit to Adding Palbociclib to Early Breast Cancer Therapy
A phase 3 trial now confirms no benefit to adding palbociclib to endocrine therapy in early HR-positive, HER2-negative breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 10, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Phase II study of Roche ’s giredestrant meets primary endpoint in the most frequently diagnosed type of breast cancer
Basel, 10 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase II coopERA Breast Cancer study met its primary endpoint in the neoadjuvant treatment of early stage ER-positive, HER2-negative breast cancer. Breast cancer is the most frequently diagnosed type of cancer, with major societal impac t.2 Hormone receptor (HR)-positive breast cancer is the most common subtype, representing ~70% of all diagnoses, or an estimated 1.6 million cases annually across the world.2,3 (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2021 Category: Pharmaceuticals Source Type: news
The Evolving HER2+ Metastatic Breast Cancer Landscape The Evolving HER2+ Metastatic Breast Cancer Landscape
Experts highlight how they are building on the recent therapeutic advances in HER2-positive MBC and how new options have begun to reshape the treatment landscape for patients.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib
Fast Track application is based on positive data in NSCLC HER2 exon 20 insertion mutations in previously treated patients
Positive Results for Cohort 2 of ZENITH20 clinical trial published in Journal of Clinical Oncology
HENDERSON,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 6, 2021 Category: Drugs & Pharmacology Source Type: news
